Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
J Clin Oncol
    July 2021
  1. BURSTEIN HJ, Somerfield MR, Barton DL, Dorris A, et al
    Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2021 Jul 29:JCO2101392. doi: 10.1200/JCO.21.01392.
    >> Share

  2. MOY B, Rumble RB, Come SE, Davidson NE, et al
    Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
    J Clin Oncol. 2021 Jul 29:JCO2101374. doi: 10.1200/JCO.21.01374.
    >> Share

  3. BODDICKER NJ, Hu C, Weitzel JN, Kraft P, et al
    Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
    J Clin Oncol. 2021 Jul 22:JCO2100531. doi: 10.1200/JCO.21.00531.
    >> Share

  4. BRACKSTONE M, Baldassarre FG, Perera FE, Cil T, et al
    Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline.
    J Clin Oncol. 2021 Jul 19:JCO2100934. doi: 10.1200/JCO.21.00934.
    >> Share

  5. KAWAMURA Y, Shimomura A, Shimizu C
    Who Can Receive the Benefit of a Palbociclib Add-On in Patients With HR+HER2- Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy?
    J Clin Oncol. 2021 Jul 6:JCO2101174. doi: 10.1200/JCO.21.01174.
    >> Share

  6. LAMBERTINI M, Blondeaux E, Bruzzone M, Perachino M, et al
    Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2021 Jul 1:JCO2100535. doi: 10.1200/JCO.21.00535.
    >> Share

    June 2021
  7. BEYER KMM, Zhou Y, Laud PW, McGinley EL, et al
    Mortgage Lending Bias and Breast Cancer Survival Among Older Women in the United States.
    J Clin Oncol. 2021 Jun 15:JCO2100112. doi: 10.1200/JCO.21.00112.
    >> Share

  8. SUEMASU T, Shimomura A, Shimizu C, Hashimoto K, et al
    Regarding the Appropriate Target and Duration of Chemoprevention in Breast Cancer.
    J Clin Oncol. 2021 Jun 14:JCO2101060. doi: 10.1200/JCO.21.01060.
    >> Share

  9. ROBSON M
    Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2.
    J Clin Oncol. 2021 Jun 9:JCO2100999. doi: 10.1200/JCO.21.00999.
    >> Share

  10. GAO C, Polley EC, Hart SN, Huang H, et al
    Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.
    J Clin Oncol. 2021 Jun 8:JCO2001992. doi: 10.1200/JCO.20.01992.
    >> Share

  11. MAYER IA, Zhao F, Arteaga CL, Symmans WF, et al
    Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
    J Clin Oncol. 2021 Jun 6:JCO2100976. doi: 10.1200/JCO.21.00976.
    >> Share

  12. TOLANEY SM, Tayob N, Dang C, Yardley DA, et al
    Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
    J Clin Oncol. 2021 Jun 2:JCO2003398. doi: 10.1200/JCO.20.03398.
    >> Share

    May 2021
  13. MOSKOWITZ CS, Ronckers CM, Chou JF, Smith SA, et al
    Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts.
    J Clin Oncol. 2021 May 28:JCO2002244. doi: 10.1200/JCO.20.02244.
    >> Share

  14. TOLANEY SM, Garrett-Mayer E, White J, Blinder VS, et al
    Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0.
    J Clin Oncol. 2021 May 18:JCO2003613. doi: 10.1200/JCO.20.03613.
    >> Share

  15. CONNOLLY RM, Leal JP, Solnes L, Huang CY, et al
    Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
    J Clin Oncol. 2021 May 17:JCO2100280. doi: 10.1200/JCO.21.00280.
    >> Share

  16. LIN NU, Pegram M, Sahebjam S, Ibrahim N, et al
    Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study.
    J Clin Oncol. 2021 May 4:JCO2002822. doi: 10.1200/JCO.20.02822.
    >> Share

    April 2021
  17. ALVA AS, Mangat PK, Garrett-Mayer E, Halabi S, et al
    Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    J Clin Oncol. 2021 Apr 12:JCO2002923. doi: 10.1200/JCO.20.02923.
    >> Share

  18. TAIRA N, Sawaki M, Uemura Y, Saito T, et al
    Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
    J Clin Oncol. 2021 Apr 9:JCO2002751. doi: 10.1200/JCO.20.02751.
    >> Share

  19. LOIBL S, Marme F, Martin M, Untch M, et al
    Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
    J Clin Oncol. 2021 Apr 1:JCO2003639. doi: 10.1200/JCO.20.03639.
    >> Share

  20. ANDO K, Shimomura A, Yoshimura K, Kawamura Y, et al
    What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?
    J Clin Oncol. 2021 Apr 1:JCO2100178. doi: 10.1200/JCO.21.00178.
    >> Share

    March 2021
  21. FASCHING PA, Yadav S, Hu C, Wunderle M, et al
    Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
    J Clin Oncol. 2021 Mar 29:JCO2001200. doi: 10.1200/JCO.20.01200.
    >> Share

  22. CIRUELOS EM, Rugo HS, Mayer IA, Levy C, et al
    Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.
    J Clin Oncol. 2021 Mar 29:JCO2001139. doi: 10.1200/JCO.20.01139.
    >> Share

  23. MCDONNELL DP, Wardell SE, Chang CY, Norris JD, et al
    Next-Generation Endocrine Therapies for Breast Cancer.
    J Clin Oncol. 2021 Mar 11:JCO2003565. doi: 10.1200/JCO.20.03565.
    >> Share

    February 2021
  24. HASHIMOTO K, Shimomura A
    Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer.
    J Clin Oncol. 2021 Feb 25:JCO2003215. doi: 10.1200/JCO.20.03215.
    >> Share

  25. KURIAN AW, Ward KC, Abrahamse P, Bondarenko I, et al
    Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
    J Clin Oncol. 2021 Feb 9:JCO2002785. doi: 10.1200/JCO.20.02785.
    >> Share

  26. PICCART M, Procter M, Fumagalli D, de Azambuja E, et al
    Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
    J Clin Oncol. 2021 Feb 4:JCO2001204. doi: 10.1200/JCO.20.01204.
    >> Share

    January 2021
  27. BARDIA A, Kaklamani V, Wilks S, Weise A, et al
    Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
    J Clin Oncol. 2021 Jan 29:JCO2002272. doi: 10.1200/JCO.20.02272.
    >> Share

  28. KORDE LA, Somerfield MR, Carey LA, Crews JR, et al
    Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
    J Clin Oncol. 2021 Jan 28:JCO2003399. doi: 10.1200/JCO.20.03399.
    >> Share

  29. MAGNUSON A, Sedrak MS, Gross CP, Tew WP, et al
    Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer.
    J Clin Oncol. 2021 Jan 14:JCO2002063. doi: 10.1200/JCO.20.02063.
    >> Share

    December 2020
  30. MCNEIL CM
    Coronavirus Farewell.
    J Clin Oncol. 2020;38:4346-4348.
    >> Share

  31. AZIM HA JR, Ameye L, Paesmans M, Lambertini M, et al
    Reply to S. A. Narod et al.
    J Clin Oncol. 2020;38:4352-4354.
    >> Share

  32. MO DC, Luo PH, Huang JF, Huang SX, et al
    Neratinib Plus Capecibine in Patients With HER2-Positive Metastatic Breast Cancer.
    J Clin Oncol. 2020 Dec 17:JCO2002378. doi: 10.1200/JCO.20.02378.
    >> Share

  33. DEKKER TJA
    Neratinib in HER2-Positive Breast Cancer With Brain Metastases.
    J Clin Oncol. 2020 Dec 17:JCO2002385. doi: 10.1200/JCO.20.02385.
    >> Share

  34. DOWSETT M, Sestak I, Cuzick J
    Calibration of CTS5 in Women With Early Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2020 Dec 16:JCO2002551. doi: 10.1200/JCO.20.02551.
    >> Share

  35. SPARANO JA, Crager MR, Tang G, Gray RJ, et al
    Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer.
    J Clin Oncol. 2020 Dec 11:JCO2003007. doi: 10.1200/JCO.20.03007.
    >> Share

  36. WRIGHT JL, Bellon JR
    Is the Time Right for Five-Fraction Partial Breast Irradiation?
    J Clin Oncol. 2020;38:4135-4137.
    >> Share

  37. BEKELMAN JE, Gupta A, Fishman E, Debono D, et al
    Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.
    J Clin Oncol. 2020;38:4055-4063.
    >> Share

  38. JAGSI R, Griffith KA, Vicini F, Boike T, et al
    Toward Improving Patients' Experiences of Acute Toxicity From Breast Radiotherapy: Insights From the Analysis of Patient-Reported Outcomes in a Large Multicenter Cohort.
    J Clin Oncol. 2020;38:4019-4029.
    >> Share

    November 2020
  39. WEINSTEIN SP, Korhonen K, Cirelli C, Schnall MD, et al
    Abbreviated Breast Magnetic Resonance Imaging for Supplemental Screening of Women With Dense Breasts and Average Risk.
    J Clin Oncol. 2020;38:3874-3882.
    >> Share

  40. RECHT A
    Hypofractionated Whole-Breast Irradiation: Case Closed?
    J Clin Oncol. 2020;38:3584-3586.
    >> Share

  41. WANG SL, Fang H, Hu C, Song YW, et al
    Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China.
    J Clin Oncol. 2020;38:3604-3614.
    >> Share

  42. ANG E
    Four Women, One Evening.
    J Clin Oncol. 2020;38:3716-3718.
    >> Share

    October 2020
  43. NAROD SA, Giannakeas V
    In Response to "Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations".
    J Clin Oncol. 2020 Oct 30:JCO2002253. doi: 10.1200/JCO.20.02253.
    >> Share

  44. TUNG NM, Robson ME, Ventz S, Santa-Maria CA, et al
    TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
    J Clin Oncol. 2020 Oct 29:JCO2002151. doi: 10.1200/JCO.20.02151.
    >> Share

  45. BUUS R, Sestak I, Kronenwett R, Ferree S, et al
    Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study.
    J Clin Oncol. 2020 Oct 27:JCO2000853. doi: 10.1200/JCO.20.00853.
    >> Share

  46. FERNANDEZ-MARTINEZ A, Krop IE, Hillman DW, Polley MY, et al
    Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
    J Clin Oncol. 2020 Oct 23:JCO2001276. doi: 10.1200/JCO.20.01276.
    >> Share

  47. DENDULURI N, Somerfield MR, Chavez-MacGregor M, Comander AH, et al
    Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2020 Oct 20:JCO2002510. doi: 10.1200/JCO.20.02510.
    >> Share

  48. BUCHHOLZ TA, Ali S, Hunt KK
    Reply to A. Thomsen et al.
    J Clin Oncol. 2020;38:3577.
    >> Share

  49. ARAOYE EF, Stearns V, Aguh C
    Considerations for the Use of Scalp Cooling Devices in Black Patients.
    J Clin Oncol. 2020;38:3575-3576.
    >> Share

  50. DALLA VOLTA A, Mazziotti G, Maffezzoni F, Grisanti S, et al
    Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies.
    J Clin Oncol. 2020;38:3363-3366.
    >> Share

  51. WHELAN T, Levine M, Sussman J
    Hypofractionated Breast Irradiation: What's Next?
    J Clin Oncol. 2020;38:3245-3247.
    >> Share

  52. MODI S, Park H, Murthy RK, Iwata H, et al
    Reply to T.J.A. Dekker.
    J Clin Oncol. 2020;38:3351-3352.
    >> Share

    September 2020
  53. MULDER RL, Hudson MM, Bhatia S, Landier W, et al
    Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group.
    J Clin Oncol. 2020 Sep 29:JCO2000562. doi: 10.1200/JCO.20.00562.
    >> Share

  54. WOLFF AC
    CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?
    J Clin Oncol. 2020 Sep 20:JCO2002688. doi: 10.1200/JCO.20.02688.
    >> Share

  55. JOHNSTON SRD, Harbeck N, Hegg R, Toi M, et al
    Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
    J Clin Oncol. 2020 Sep 20:JCO2002514. doi: 10.1200/JCO.20.02514.
    >> Share

  56. DE AZAMBUJA E, Ponde N, Gelber RD
    Are We RESPECTing Older Patients With Breast Cancer?
    J Clin Oncol. 2020 Sep 16:JCO2002329. doi: 10.1200/JCO.20.02329.
    >> Share

  57. SAWAKI M, Taira N, Uemura Y, Saito T, et al
    Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
    J Clin Oncol. 2020 Sep 16:JCO2000184. doi: 10.1200/JCO.20.00184.
    >> Share

  58. OFFERSEN BV, Alsner J, Nielsen HM, Jakobsen EH, et al
    Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial.
    J Clin Oncol. 2020 Sep 10:JCO2001363. doi: 10.1200/JCO.20.01363.
    >> Share

  59. LIGIBEL JA
    Reply to R.T. Chlebowski et al.
    J Clin Oncol. 2020;38:3072-3073.
    >> Share

  60. THOMSEN AR, Vaupel P, Grosu AL, Notter M, et al
    Hyperthermia Plus Re-Irradiation in the Management of Unresectable Locoregional Recurrence of Breast Cancer in Previously Irradiated Sites.
    J Clin Oncol. 2020 Sep 8:JCO2001857. doi: 10.1200/JCO.20.01857.
    >> Share

    August 2020
  61. MEATTINI I, Marrazzo L, Saieva C, Desideri I, et al
    Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial.
    J Clin Oncol. 2020 Aug 24:JCO2000650. doi: 10.1200/JCO.20.00650.
    >> Share

  62. JOHNSTON SRD, Hegg R, Im SA, Park IH, et al
    Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Br
    J Clin Oncol. 2020 Aug 21:JCO2001894. doi: 10.1200/JCO.20.01894.
    >> Share

  63. JAFFE ES, Feldman AL, Gaulard P, Miranda RN, et al
    Reply to M. Romero et al.
    J Clin Oncol. 2020;38:2819-2820.
    >> Share

  64. TUNG N, Hacker MR, Garber JE
    Reply to S. Takamizawa et al.
    J Clin Oncol. 2020;38:2700-2701.
    >> Share

  65. TING FIL
    The Road Less Traveled: Serving the Underserved.
    J Clin Oncol. 2020;38:2597-2598.
    >> Share

    July 2020
  66. NAOUM GE, Roberts S, Brunelle CL, Shui AM, et al
    Quantifying the Impact of Axillary Surgery and Nodal Irradiation on Breast Cancer-Related Lymphedema and Local Tumor Control: Long-Term Results From a Prospective Screening Trial.
    J Clin Oncol. 2020 Jul 30:JCO2000459. doi: 10.1200/JCO.20.00459.
    >> Share

  67. RAHBAR H, Lee JM, Lee CI
    Optimal Screening in Breast Cancer Survivors With Dense Breasts on Mammography.
    J Clin Oncol. 2020 Jul 24:JCO2001641. doi: 10.1200/JCO.20.01641.
    >> Share

  68. NOORDHOEK I, Blok EJ, Meershoek-Klein Kranenbarg E, Putter H, et al
    Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
    J Clin Oncol. 2020 Jul 24:JCO1902427. doi: 10.1200/JCO.19.02427.
    >> Share

  69. SAURA C, Oliveira M, Feng YH, Dai MS, et al
    Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >/= 2 HER2-Directed Regimens: Phase III NALA Trial.
    J Clin Oncol. 2020 Jul 17:JCO2000147. doi: 10.1200/JCO.20.00147.
    >> Share

  70. MCDONALD AM, Chen Y, Wu J, Hageman L, et al
    Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report.
    J Clin Oncol. 2020 Jul 16:JCO2000231. doi: 10.1200/JCO.20.00231.
    >> Share

  71. LAMBERTINI M, Ameye L, Hamy AS, Zingarello A, et al
    Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations.
    J Clin Oncol. 2020 Jul 16:JCO1902399. doi: 10.1200/JCO.19.02399.
    >> Share

  72. BRUNT AM, Haviland JS, Sydenham M, Agrawal RK, et al
    Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.
    J Clin Oncol. 2020 Jul 14:JCO1902750. doi: 10.1200/JCO.19.02750.
    >> Share

  73. DEKKER TJA
    HER2-Targeted Therapies in HER2-Low-Expressing Breast Cancer.
    J Clin Oncol. 2020 Jul 13:JCO2000657. doi: 10.1200/JCO.20.00657.
    >> Share

  74. SHUMWAY DA, Momoh AO, Sabel MS, Jagsi R, et al
    Integration of Breast Reconstruction and Postmastectomy Radiotherapy.
    J Clin Oncol. 2020;38:2329-2340.
    >> Share

  75. MORROW M, Khan AJ
    Locoregional Management After Neoadjuvant Chemotherapy.
    J Clin Oncol. 2020;38:2281-2289.
    >> Share

  76. HWANG ES, Solin L
    De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer.
    J Clin Oncol. 2020;38:2230-2239.
    >> Share

  77. WHITE J, Thompson A, Whelan T
    Accelerated Partial Breast Irradiation and Intraoperative Partial Breast Irradiation: Reducing the Burden of Effective Breast Conservation.
    J Clin Oncol. 2020;38:2254-2262.
    >> Share

  78. MAMOUNAS EP, Mitchell MP, Woodward WA
    Molecular Predictive and Prognostic Markers in Locoregional Management.
    J Clin Oncol. 2020;38:2310-2320.
    >> Share

  79. DESMEDT C, Fornili M, Clatot F, Demicheli R, et al
    Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.
    J Clin Oncol. 2020 Jul 2:JCO1901771. doi: 10.1200/JCO.19.01771.
    >> Share

  80. CHLEBOWSKI RT, Aragaki AK, Prentice RL
    Dietary Moderation and Deaths From Breast Cancer.
    J Clin Oncol. 2020 Jul 2:JCO2001218. doi: 10.1200/JCO.20.01218.
    >> Share

  81. CATHCART-RAKE EJ, Ruddy KJ
    Smart Technology and Endocrine Therapy Adherence.
    J Clin Oncol. 2020;38:2117-2118.
    >> Share

    June 2020
  82. PISTILLI B, Paci A, Ferreira AR, Di Meglio A, et al
    Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk.
    J Clin Oncol. 2020 Jun 22:JCO1901758. doi: 10.1200/JCO.19.01758.
    >> Share

  83. LLUCH A, Barrios CH, Torrecillas L, Martin M, et al
    Reply to Y. Usui et al.
    J Clin Oncol. 2020;38:2113-2114.
    >> Share

  84. AMBROSONE CB, Hutson AD
    Reply to E. Javor et al.
    J Clin Oncol. 2020;38:2111.
    >> Share

  85. ROMERO M, Melo A, Bedoya N, de la Hoz J, et al
    Should Flow Cytometry Be Considered a First Line of Study in the Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma?
    J Clin Oncol. 2020 Jun 17:JCO2000712. doi: 10.1200/JCO.20.00712.
    >> Share

  86. TAKAMIZAWA S, Ishiki H, Shimoi T, Shimizu M, et al
    Neoadjuvant Cisplatin in BRCA Carriers With HER2-Negative Breast Cancer.
    J Clin Oncol. 2020 Jun 9:JCO2000789. doi: 10.1200/JCO.20.00789.
    >> Share

    May 2020
  87. LIN NU, Borges V, Anders C, Murthy RK, et al
    Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
    J Clin Oncol. 2020 May 29:JCO2000775. doi: 10.1200/JCO.20.00775.
    >> Share

  88. TORRES MA, Horst KC, Freedman GM
    Postmastectomy and Regional Nodal Radiation for Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902908. doi: 10.1200/JCO.19.02908.
    >> Share

  89. MITTENDORF EA, Bellon JR, King TA
    Regional Nodal Management in Patients With Clinically Node-Negative Breast Cancer Undergoing Upfront Surgery.
    J Clin Oncol. 2020 May 22:JCO1902891. doi: 10.1200/JCO.19.02891.
    >> Share

  90. HEPEL JT, Wazer DE
    Partial Breast Irradiation Is the Preferred Standard of Care for a Majority of Women With Early-Stage Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902594. doi: 10.1200/JCO.19.02594.
    >> Share

  91. SMITH BD, Goetz MP, Boughey JC
    Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement.
    J Clin Oncol. 2020 May 22:JCO1903036. doi: 10.1200/JCO.19.03036.
    >> Share

  92. RECHT A
    Whole-Breast Irradiation Is the Preferred Standard of Care for the Majority of Patients With Early-Stage Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902388. doi: 10.1200/JCO.19.02388.
    >> Share

  93. SHAITELMAN SF, Jeruss JS, Pusic AL
    Oncoplastic Surgery in the Management of Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902795. doi: 10.1200/JCO.19.02795.
    >> Share

  94. KUHL CK, Lehman C, Bedrosian I
    Imaging in Locoregional Management of Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1903257. doi: 10.1200/JCO.19.03257.
    >> Share

  95. SCHNITT SJ, Moran MS, Giuliano AE
    Lumpectomy Margins for Invasive Breast Cancer and Ductal Carcinoma in Situ: Current Guideline Recommendations, Their Implications, and Impact.
    J Clin Oncol. 2020 May 22:JCO1903213. doi: 10.1200/JCO.19.03213.
    >> Share

  96. MCLAUGHLIN SA, Brunelle CL, Taghian A
    Breast Cancer-Related Lymphedema: Risk Factors, Screening, Management, and the Impact of Locoregional Treatment.
    J Clin Oncol. 2020 May 22:JCO1902896. doi: 10.1200/JCO.19.02896.
    >> Share

  97. HAFFTY BG, Euhus DM, Pierce LJ
    Genetic Factors in the Locoregional Management of Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902859. doi: 10.1200/JCO.19.02859.
    >> Share

  98. SMITH BD, Mittendorf EA, Haffty BG
    Multidisciplinary Locoregional Management of Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO2000483. doi: 10.1200/JCO.20.00483.
    >> Share

  99. BUCHHOLZ TA, Ali S, Hunt KK
    Multidisciplinary Management of Locoregional Recurrent Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902806. doi: 10.1200/JCO.19.02806.
    >> Share

  100. HERSHMAN DL, Unger JM, Hillyer GC, Moseley A, et al
    Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105.
    J Clin Oncol. 2020 May 5:JCO1902699. doi: 10.1200/JCO.19.02699.
    >> Share

    April 2020
  101. USUI Y, Ishiki H, Shimomura A, Satomi E, et al
    Suggestions Regarding the GEICAM/2003-11_CIBOMA/2004-01 Trial: Future Treatment Options for Early Triple-Negative Breast Cancer.
    J Clin Oncol. 2020 Apr 30:JCO1903406. doi: 10.1200/JCO.19.03406.
    >> Share

  102. TARANTINO P, Hamilton E, Tolaney SM, Cortes J, et al
    HER2-Low Breast Cancer: Pathological and Clinical Landscape.
    J Clin Oncol. 2020 Apr 24:JCO1902488. doi: 10.1200/JCO.19.02488.
    >> Share

  103. JAVOR E, Lucijanic M, Skelin M
    Dietary Supplement Use and Patient Outcomes in High-Risk Early-Stage Breast Cancer.
    J Clin Oncol. 2020 Apr 21:JCO2000091. doi: 10.1200/JCO.20.00091.
    >> Share

  104. LAZZERONI M, DeCensi A
    De-Escalating Treatment of Low-Risk Breast Ductal Carcinoma In Situ.
    J Clin Oncol. 2020;38:1252-1254.
    >> Share

  105. HWANG ES, Hyslop T, Hendrix LH, Duong S, et al
    Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
    J Clin Oncol. 2020;38:1284-1292.
    >> Share

  106. PAGANI O, Francis PA, Fleming GF, Walley BA, et al
    Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
    J Clin Oncol. 2020;38:1293-1303.
    >> Share

  107. LI J, Yu K, Pang D, Wang C, et al
    Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
    J Clin Oncol. 2020 Apr 10:JCO1902474. doi: 10.1200/JCO.19.02474.
    >> Share

  108. WAGNER LI, Gray RJ, Sparano JA, Whelan TJ, et al
    Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.
    J Clin Oncol. 2020 Apr 9:JCO1901866. doi: 10.1200/JCO.19.01866.
    >> Share

  109. HORTOBAGYI GN
    Breast Cancer: 45 Years of Research and Progress.
    J Clin Oncol. 2020 Apr 7:JCO2000199. doi: 10.1200/JCO.20.00199.
    >> Share

  110. TUNG NM, Boughey JC, Pierce LJ, Robson ME, et al
    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
    J Clin Oncol. 2020 Apr 3:JCO2000299. doi: 10.1200/JCO.20.00299.
    >> Share

  111. STEBBING J, Mainwaring PN, Curigliano G, Pegram M, et al
    Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
    J Clin Oncol. 2020;38:1070-1080.
    >> Share

  112. CHIEN AJ, Tripathy D, Albain KS, Symmans WF, et al
    MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
    J Clin Oncol. 2020;38:1059-1069.
    >> Share

    March 2020
  113. BEEBE-DIMMER JL, Kapron AL, Fraser AM, Smith KR, et al
    Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
    J Clin Oncol. 2020 Mar 24:JCO1902808. doi: 10.1200/JCO.19.02808.
    >> Share

  114. LIGIBEL JA
    Could the Women's Health Initiative Breathe New Life Into Breast Cancer Prevention?
    J Clin Oncol. 2020 Mar 9:JCO2000148. doi: 10.1200/JCO.20.00148.
    >> Share

  115. GANZ PA, Van Dyk K
    Cognitive Impairment in Patients With Breast Cancer: Understanding the Impact of Chemotherapy and Endocrine Therapy.
    J Clin Oncol. 2020 Mar 6:JCO2000336. doi: 10.1200/JCO.20.00336.
    >> Share

  116. YADAV S, Hu C, Hart SN, Boddicker N, et al
    Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
    J Clin Oncol. 2020 Mar 3:JCO1902190. doi: 10.1200/JCO.19.02190.
    >> Share

  117. YANG X, Leslie G, Doroszuk A, Schneider S, et al
    Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
    J Clin Oncol. 2020;38:674-685.
    >> Share

    February 2020
  118. TUNG N, Arun B, Hacker MR, Hofstatter E, et al
    TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).
    J Clin Oncol. 2020 Feb 25:JCO1903292. doi: 10.1200/JCO.19.03292.
    >> Share

  119. DELALOGE S, Piccart M, Rutgers E, Litiere S, et al
    Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
    J Clin Oncol. 2020 Feb 21:JCO1901371. doi: 10.1200/JCO.19.01371.
    >> Share

  120. MODI S, Park H, Murthy RK, Iwata H, et al
    Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
    J Clin Oncol. 2020 Feb 14:JCO1902318. doi: 10.1200/JCO.19.02318.
    >> Share

  121. HASSETT MJ, Somerfield MR, Baker ER, Cardoso F, et al
    Management of Male Breast Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Feb 14:JCO1903120. doi: 10.1200/JCO.19.03120.
    >> Share

  122. JAFFE ES, Ashar BS, Clemens MW, Feldman AL, et al
    Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.
    J Clin Oncol. 2020 Feb 11:JCO1902778. doi: 10.1200/JCO.19.02778.
    >> Share

  123. CHLEBOWSKI RT, Aragaki AK, Anderson GL, Pan K, et al
    Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Women's Health Initiative Randomized Trial.
    J Clin Oncol. 2020 Feb 7:JCO1900435. doi: 10.1200/JCO.19.00435.
    >> Share

    January 2020
  124. RAYSON D
    Camouflage.
    J Clin Oncol. 2020;38:281-282.
    >> Share

  125. ALLISON KH, Hammond MEH, Dowsett M, McKernin SE, et al
    Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
    J Clin Oncol. 2020 Jan 13:JCO1902309. doi: 10.1200/JCO.19.02309.
    >> Share

  126. GEIERSBACH KB, Meyer RG, Sill DR, Mounajjed T, et al
    Working Up Group 4 Equivocal HER2 Samples Tested by Fluorescence in Situ Hybridization in a Reference Laboratory Setting: Past, Present, and Future.
    J Clin Oncol. 2020;38:175-176.
    >> Share

  127. HENRY NL, Andre F, Ismaila N, Somerfield MR, et al
    Reply to A. Katz.
    J Clin Oncol. 2020;38:102-103.
    >> Share

  128. KATZ A
    Is It Appropriate to Use the Result of an Unplanned, Exploratory, Nonstatistically Significant Subgroup Analysis to Support a Treatment Recommendation in an ASCO Treatment Guideline?
    J Clin Oncol. 2020;38:102.
    >> Share

    December 2019
  129. HAYES DF, Rae JM
    Pharmacogenomics and Endocrine Therapy in Breast Cancer.
    J Clin Oncol. 2019 Dec 27:JCO1903119. doi: 10.1200/JCO.19.03119.
    >> Share

  130. AMBROSONE CB, Zirpoli GR, Hutson AD, McCann WE, et al
    Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221).
    J Clin Oncol. 2019 Dec 19:JCO1901203. doi: 10.1200/JCO.19.01203.
    >> Share

  131. SCHMID P, Abraham J, Chan S, Wheatley D, et al
    Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
    J Clin Oncol. 2019 Dec 16:JCO1900368. doi: 10.1200/JCO.19.00368.
    >> Share

  132. DUMAS A, Vaz Luis I, Bovagnet T, El Mouhebb M, et al
    Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO).
    J Clin Oncol. 2019 Dec 13:JCO1901726. doi: 10.1200/JCO.19.01726.
    >> Share

  133. FEHRENBACHER L, Cecchini RS, Geyer CE Jr, Rastogi P, et al
    NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
    J Clin Oncol. 2019 Dec 10:JCO1901455. doi: 10.1200/JCO.19.01455.
    >> Share

  134. TAMURA K, Imamura CK, Takano T, Saji S, et al
    CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.
    J Clin Oncol. 2019 Dec 10:JCO1901412. doi: 10.1200/JCO.19.01412.
    >> Share

  135. POORVU PD, Gelber SI, Rosenberg SM, Ruddy KJ, et al
    Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
    J Clin Oncol. 2019 Dec 6:JCO1901959. doi: 10.1200/JCO.19.01959.
    >> Share

  136. LLUCH A, Barrios CH, Torrecillas L, Ruiz-Borrego M, et al
    Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
    J Clin Oncol. 2019 Dec 5:JCO1900904. doi: 10.1200/JCO.19.00904.
    >> Share

  137. VARSHAVSKY-YANOVSKY AN, Goldstein LJ
    Role of Capecitabine in Early Breast Cancer.
    J Clin Oncol. 2019 Dec 5:JCO1902946. doi: 10.1200/JCO.19.02946.
    >> Share

  138. JAYASEKERA J, Mandelblatt JS
    Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions.
    J Clin Oncol. 2019 Dec 5:JCO1901525. doi: 10.1200/JCO.19.01525.
    >> Share

  139. HE W, Grassmann F, Eriksson M, Eliasson E, et al
    CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer.
    J Clin Oncol. 2019 Dec 4:JCO1901535. doi: 10.1200/JCO.19.01535.
    >> Share

    October 2019
  140. SHARMA P, Barlow WE, Godwin AK, Parkes EE, et al
    Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
    J Clin Oncol. 2019 Oct 28:JCO1900693. doi: 10.1200/JCO.19.00693.
    >> Share

  141. CHUMSRI S, Li Z, Serie DJ, Mashadi-Hossein A, et al
    Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31.
    J Clin Oncol. 2019 Oct 17:JCO1900443. doi: 10.1200/JCO.19.00443.
    >> Share

  142. SJOSTROM M, Chang SL, Fishbane N, Davicioni E, et al
    Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer.
    J Clin Oncol. 2019 Oct 16:JCO1900761. doi: 10.1200/JCO.19.00761.
    >> Share

  143. LAMBERTINI M, Blondeaux E, Perrone F, Del Mastro L, et al
    Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer.
    J Clin Oncol. 2019 Oct 16:JCO1902242. doi: 10.1200/JCO.19.02242.
    >> Share

    September 2019
  144. HOWIE LJ, Singh H, Bloomquist E, Wedam S, et al
    Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.
    J Clin Oncol. 2019 Sep 27:JCO1802217. doi: 10.1200/JCO.18.02217.
    >> Share

  145. KIM HA, Lee JW, Nam SJ, Park BW, et al
    Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial.
    J Clin Oncol. 2019 Sep 16:JCO1900126. doi: 10.1200/JCO.19.00126.
    >> Share

  146. VISVANATHAN K, Fabian CJ, Bantug E, Brewster AM, et al
    Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update.
    J Clin Oncol. 2019 Sep 3:JCO1901472. doi: 10.1200/JCO.19.01472.
    >> Share

    August 2019
  147. HINDIE E
    Skipping the Lymphoscintigraphy Step During Sentinel Node Procedures in Breast Cancer: What Information Are We Missing?
    J Clin Oncol. 2019 Aug 29:JCO1901612. doi: 10.1200/JCO.19.01612.
    >> Share

  148. LITTON JK, Scoggins ME, Hess KR, Adrada BE, et al
    Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.
    J Clin Oncol. 2019 Aug 28:JCO1901304. doi: 10.1200/JCO.19.01304.
    >> Share

  149. JIMENEZ RB, Hickey S, DePauw N, Yeap BY, et al
    Phase II Study of Proton Beam Radiation Therapy for Patients With Breast Cancer Requiring Regional Nodal Irradiation.
    J Clin Oncol. 2019 Aug 26:JCO1802366. doi: 10.1200/JCO.18.02366.
    >> Share

  150. ABRAHAM J, Montero AJ, Jankowitz RC, Salkeni MA, et al
    Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.
    J Clin Oncol. 2019 Aug 23:JCO1900858. doi: 10.1200/JCO.19.00858.
    >> Share

  151. MA F, Ouyang Q, Li W, Jiang Z, et al
    Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
    J Clin Oncol. 2019 Aug 20:JCO1900108. doi: 10.1200/JCO.19.00108.
    >> Share

  152. CESPEDES FELICIANO EM, Chen WY, Bradshaw PT, Prado CM, et al
    Adipose Tissue Distribution and Cardiovascular Disease Risk Among Breast Cancer Survivors.
    J Clin Oncol. 2019 Aug 1:JCO1900286. doi: 10.1200/JCO.19.00286.
    >> Share

    July 2019
  153. MUSS HB, Polley MC, Berry DA, Liu H, et al
    Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
    J Clin Oncol. 2019 Jul 24:JCO1900647. doi: 10.1200/JCO.19.00647.
    >> Share

  154. ROSS M, Geyer CE Jr
    Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?
    J Clin Oncol. 2019 Jul 15:JCO1900877. doi: 10.1200/JCO.19.00877.
    >> Share

  155. MOSKOWITZ CS, Chou JF, Neglia JP, Partridge AH, et al
    Mortality After Breast Cancer Among Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
    J Clin Oncol. 2019 Jul 1:JCO1802219. doi: 10.1200/JCO.18.02219.
    >> Share

  156. OEFFINGER KC, Ford JS, Moskowitz CS, Chou JF, et al
    Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study.
    J Clin Oncol. 2019 Jul 1:JCO1900547. doi: 10.1200/JCO.19.00547.
    >> Share

    June 2019
  157. HINDIE E, Groheux D
    Interim [(18)F]Fluorodeoxyglucose-Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2019 Jun 28:JCO1900776. doi: 10.1200/JCO.19.00776.
    >> Share

  158. RAJAGOPAL PS, Catenacci DVT, Olopade OI
    The Time for Mainstreaming Germline Testing for Patients With Breast Cancer Is Now.
    J Clin Oncol. 2019 Jun 27:JCO1900160. doi: 10.1200/JCO.19.00160.
    >> Share

  159. TAYLOR A, Tischkowitz M
    Caveat Emptor: The Perils of Panel Testing in Hereditary Breast Cancer.
    J Clin Oncol. 2019 Jun 27:JCO1900122. doi: 10.1200/JCO.19.00122.
    >> Share

  160. COPUR MS, Jonglertham P, Zusag T
    Should All Patients With a Diagnosis of Breast Cancer Undergo Expanded Panel Testing?
    J Clin Oncol. 2019 Jun 27:JCO1900064. doi: 10.1200/JCO.19.00064.
    >> Share

  161. GOETZ MP, Suman VJ, Nakamura Y, Kiyotani K, et al
    Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM.
    J Clin Oncol. 2019 Jun 18:JCO1900504. doi: 10.1200/JCO.19.00504.
    >> Share

  162. HENRY NL, Somerfield MR, Abramson VG, Ismaila N, et al
    Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
    J Clin Oncol. 2019 Jun 17:JCO1900948. doi: 10.1200/JCO.19.00948.
    >> Share

  163. KANTOR ED, Romano ME
    Phthalate Exposure From Prescription Medications and Breast Cancer Risk.
    J Clin Oncol. 2019 Jun 7:JCO1901003. doi: 10.1200/JCO.19.01003.
    >> Share

  164. CONFORTI F, Pala L
    Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors.
    J Clin Oncol. 2019 Jun 7:JCO1900559. doi: 10.1200/JCO.19.00559.
    >> Share

  165. HURVITZ SA, Martin M, Jung KH, Huang CS, et al
    Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
    J Clin Oncol. 2019 Jun 3:JCO1900882. doi: 10.1200/JCO.19.00882.
    >> Share

  166. WOLFF AC, Tung NM, Carey LA
    Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2019 Jun 3:JCO1901159. doi: 10.1200/JCO.19.01159.
    >> Share

    May 2019
  167. ANDRE F, Ismaila N, Henry NL, Somerfield MR, et al
    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
    J Clin Oncol. 2019 May 31:JCO1900945. doi: 10.1200/JCO.19.00945.
    >> Share

  168. SMITH TG, Troeschel AN, Castro KM, Arora NK, et al
    Perceptions of Patients With Breast and Colon Cancer of the Management of Cancer-Related Pain, Fatigue, and Emotional Distress in Community Oncology.
    J Clin Oncol. 2019 May 17:JCO1801579. doi: 10.1200/JCO.18.01579.
    >> Share

  169. FABIAN CJ
    Will a Low-Dose Option Improve Uptake of Tamoxifen for Breast Cancer Risk Reduction?
    J Clin Oncol. 2019 May 13:JCO1900656. doi: 10.1200/JCO.19.00656.
    >> Share

  170. UNTCH M, Jackisch C, Schneeweiss A, Schmatloch S, et al
    NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
    J Clin Oncol. 2019 May 13:JCO1801842. doi: 10.1200/JCO.18.01842.
    >> Share

  171. EHRHARDT MJ, Howell CR, Hale K, Baassiri MJ, et al
    Subsequent Breast Cancer in Female Childhood Cancer Survivors in the St Jude Lifetime Cohort Study (SJLIFE).
    J Clin Oncol. 2019 May 10:JCO1801099. doi: 10.1200/JCO.18.01099.
    >> Share

  172. KUEMMEL S, Holtschmidt J, Gerber B, Von der Assen A, et al
    Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial.
    J Clin Oncol. 2019 May 1:JCO1802092. doi: 10.1200/JCO.18.02092.
    >> Share

    April 2019
  173. YU KD, Shao ZM
    Comparison of Time-Dependent Contralateral Breast Cancer Incidence Requires Comparable Lengths of Follow-Up.
    J Clin Oncol. 2019 Apr 29:JCO1802468. doi: 10.1200/JCO.18.02468.
    >> Share

  174. AHERN TP, Broe A, Lash TL, Cronin-Fenton DP, et al
    Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study.
    J Clin Oncol. 2019 Apr 17:JCO1802202. doi: 10.1200/JCO.18.02202.
    >> Share

  175. KURIAN AW, Ward KC, Howlader N, Deapen D, et al
    Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
    J Clin Oncol. 2019 Apr 9:JCO1801854. doi: 10.1200/JCO.18.01854.
    >> Share

  176. FOLDI J, O'Meara T, Marczyk M, Sanft T, et al
    Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools.
    J Clin Oncol. 2019 Apr 3:JCO1801933. doi: 10.1200/JCO.18.01933.
    >> Share

  177. TOLANEY SM, Guo H, Pernas S, Barry WT, et al
    Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2019 Apr 2:JCO1900066. doi: 10.1200/JCO.19.00066.
    >> Share

    March 2019
  178. CHANDARLAPATY S, Razavi P
    Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors.
    J Clin Oncol. 2019 Mar 28:JCO1900090. doi: 10.1200/JCO.19.00090.
    >> Share

  179. FREEDMAN RA, Gelman RS, Anders CK, Melisko ME, et al
    TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
    J Clin Oncol. 2019 Mar 12:JCO1801511. doi: 10.1200/JCO.18.01511.
    >> Share

    February 2019
  180. REGAN MM, Fleming GF, Walley B, Francis PA, et al
    Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.
    J Clin Oncol. 2019 Feb 27:JCO1802433. doi: 10.1200/JCO.18.02433.
    >> Share

  181. TURNER NC, Liu Y, Zhu Z, Loi S, et al
    Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
    J Clin Oncol. 2019 Feb 26:JCO1800925. doi: 10.1200/JCO.18.00925.
    >> Share

  182. NITZ U, Gluz O, Clemens M, Malter W, et al
    West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
    J Clin Oncol. 2019 Feb 20:JCO1800028. doi: 10.1200/JCO.18.00028.
    >> Share

  183. ATEMA V, van Leeuwen M, Kieffer JM, Oldenburg HSA, et al
    Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial.
    J Clin Oncol. 2019 Feb 14:JCO1800655. doi: 10.1200/JCO.18.00655.
    >> Share

  184. PAN K, Bosserman LD, Chlebowski RT
    Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    J Clin Oncol. 2019 Feb 11:JCO1801360. doi: 10.1200/JCO.18.01360.
    >> Share

  185. DOWSETT M, Turner N
    Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk.
    J Clin Oncol. 2019 Feb 11:JCO1801412. doi: 10.1200/JCO.18.01412.
    >> Share

  186. CONNOLLY RM, Leal JP, Solnes L, Huang CY, et al
    TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
    J Clin Oncol. 2019 Feb 5:JCO2018787986. doi: 10.1200/JCO.2018.78.7986.
    >> Share

    January 2019
  187. HAMY AS, Tury S, Wang X, Gao J, et al
    Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
    J Clin Oncol. 2019 Jan 31:JCO1800636. doi: 10.1200/JCO.18.00636.
    >> Share

  188. ARASU VA, Miglioretti DL, Sprague BL, Alsheik NH, et al
    Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk.
    J Clin Oncol. 2019 Jan 9:JCO1800378. doi: 10.1200/JCO.18.00378.
    >> Share

    December 2018
  189. DELLAPASQUA S, Gray KP, Munzone E, Rubino D, et al
    Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.
    J Clin Oncol. 2018 Dec 27:JCO1800296. doi: 10.1200/JCO.18.00296.
    >> Share

  190. BEITSCH PD, Whitworth PW, Hughes K, Patel R, et al
    Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
    J Clin Oncol. 2018 Dec 7:JCO1801631. doi: 10.1200/JCO.18.01631.
    >> Share

  191. MILLIRON KJ, Griggs JJ
    Advances in Genetic Testing in Patients With Breast Cancer, High-Quality Decision Making, and Responsible Resource Allocation.
    J Clin Oncol. 2018 Dec 7:JCO1801952. doi: 10.1200/JCO.18.01952.
    >> Share

  192. JOHNSTON S, Puhalla S, Wheatley D, Ring A, et al
    Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
    J Clin Oncol. 2018 Dec 6:JCO1801624. doi: 10.1200/JCO.18.01624.
    >> Share

    November 2018
  193. RUHSTALLER T, Giobbie-Hurder A, Colleoni M, Jensen MB, et al
    Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
    J Clin Oncol. 2018 Nov 26:JCO1800440. doi: 10.1200/JCO.18.00440.
    >> Share

  194. BURSTEIN HJ, Lacchetti C, Anderson H, Buchholz TA, et al
    Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
    J Clin Oncol. 2018 Nov 19:JCO1801160. doi: 10.1200/JCO.18.01160.
    >> Share

    October 2018
  195. MANDELBLATT JS, Small BJ, Luta G, Hurria A, et al
    Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study.
    J Clin Oncol. 2018 Oct 3:JCO1800140. doi: 10.1200/JCO.18.00140.
    >> Share

    September 2018
  196. CRUZ C, Llop-Guevara A, Garber JE, Arun BK, et al
    Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
    J Clin Oncol. 2018 Sep 21:JCO2018786558. doi: 10.1200/JCO.2018.78.6558.
    >> Share

  197. BARDIA A, Parton M, Kummel S, Estevez LG, et al
    Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.
    J Clin Oncol. 2018 Sep 20:JCO2017748392. doi: 10.1200/JCO.2017.74.8392.
    >> Share

  198. SEIDMAN AD, Bordeleau L, Fehrenbacher L, Barlow WE, et al
    National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.
    J Clin Oncol. 2018 Sep 13:JCO1800242. doi: 10.1200/JCO.18.00242.
    >> Share

  199. BEAU AB, Andersen PK, Vejborg I, Lynge E, et al
    Limitations in the Effect of Screening on Breast Cancer Mortality.
    J Clin Oncol. 2018 Sep 4:JCO2018780270. doi: 10.1200/JCO.2018.78.0270.
    >> Share

    August 2018
  200. GINSBURG O, Brennan P
    Genetic Testing for Breast Cancer in the Era of Multigene Panels: Can We Make an Impact on Population Health?
    J Clin Oncol. 2018 Aug 21:JCO2018793307. doi: 10.1200/JCO.2018.79.3307.
    >> Share

  201. ZHENG Y, Walsh T, Gulsuner S, Casadei S, et al
    Inherited Breast Cancer in Nigerian Women.
    J Clin Oncol. 2018 Aug 21:JCO2018783977. doi: 10.1200/JCO.2018.78.3977.
    >> Share

  202. RIMAWI M, Ferrero JM, de la Haba-Rodriguez J, Poole C, et al
    First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase I
    J Clin Oncol. 2018 Aug 14:JCO2017767863. doi: 10.1200/JCO.2017.76.7863.
    >> Share

    July 2018
  203. PARKER PA, Peterson SK, Shen Y, Bedrosian I, et al
    Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer.
    J Clin Oncol. 2018 Jul 25:JCO2018786442. doi: 10.1200/JCO.2018.78.6442.
    >> Share

  204. MILLER KD, O'Neill A, Gradishar W, Hobday TJ, et al
    Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).
    J Clin Oncol. 2018 Jul 24:JCO2018792028. doi: 10.1200/JCO.2018.79.2028.
    >> Share

  205. HOUSTON TP, Ostroff JS
    Cardiovascular Risk Factors and Breast Cancer.
    J Clin Oncol. 2018 Jul 23:JCO1800041. doi: 10.1200/JCO.18.00041.
    >> Share

  206. HU JJ, Urbanic JJ, Case LD, Takita C, et al
    Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population.
    J Clin Oncol. 2018 Jul 10:JCO2017771790. doi: 10.1200/JCO.2017.77.1790.
    >> Share

    June 2018
  207. RAMAKRISHNA N, Temin S, Chandarlapaty S, Crews JR, et al
    Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.
    J Clin Oncol. 2018 Jun 25:JCO2018792713. doi: 10.1200/JCO.2018.79.2713.
    >> Share

  208. GIORDANO SH, Temin S, Chandarlapaty S, Crews JR, et al
    Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.
    J Clin Oncol. 2018 Jun 25:JCO2018792697. doi: 10.1200/JCO.2018.79.2697.
    >> Share

  209. LYMAN GH, Greenlee H, Bohlke K, Bao T, et al
    Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.
    J Clin Oncol. 2018 Jun 11:JCO2018792721. doi: 10.1200/JCO.2018.79.2721.
    >> Share

  210. SLAMON DJ, Neven P, Chia S, Fasching PA, et al
    Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
    J Clin Oncol. 2018 Jun 3:JCO2018789909. doi: 10.1200/JCO.2018.78.9909.
    >> Share

    May 2018
  211. WOLFF AC, Hammond MEH, Allison KH, Harvey BE, et al
    Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
    J Clin Oncol. 2018 May 30:JCO2018778738. doi: 10.1200/JCO.2018.77.8738.
    >> Share

  212. FASCHING PA, Loibl S, Hu C, Hart SN, et al
    BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
    J Clin Oncol. 2018 May 23:JCO2017772285. doi: 10.1200/JCO.2017.77.2285.
    >> Share

  213. TAYLOR C, McGale P, Bronnum D, Correa C, et al
    Cardiac Structure Injury After Radiotherapy for Breast Cancer: Cross-Sectional Study With Individual Patient Data.
    J Clin Oncol. 2018 May 23:JCO2017776351. doi: 10.1200/JCO.2017.77.6351.
    >> Share

  214. THAVENDIRANATHAN P, Abdel-Qadir H, Fischer HD, Liu Y, et al
    Risk-Imaging Mismatch in Cardiac Imaging Practices for Women Receiving Systemic Therapy for Early-Stage Breast Cancer: A Population-Based Cohort Study.
    J Clin Oncol. 2018 May 23:JCO2018779736. doi: 10.1200/JCO.2018.77.9736.
    >> Share

  215. DENDULURI N, Chavez-MacGregor M, Telli ML, Eisen A, et al
    Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
    J Clin Oncol. 2018 May 22:JCO2018788604. doi: 10.1200/JCO.2018.78.8604.
    >> Share

  216. WANG L, Hong BY, Kennedy SA, Chang Y, et al
    Predictors of Unemployment After Breast Cancer Surgery: A Systematic Review and Meta-Analysis of Observational Studies.
    J Clin Oncol. 2018 May 14:JCO2017773663. doi: 10.1200/JCO.2017.77.3663.
    >> Share

  217. LAMBERTINI M, Moore HCF, Leonard RCF, Loibl S, et al
    Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
    J Clin Oncol. 2018 May 2:JCO2018780858. doi: 10.1200/JCO.2018.78.0858.
    >> Share

    April 2018
  218. SHERMAN KA, Przezdziecki A, Alcorso J, Kilby CJ, et al
    Reducing Body Image-Related Distress in Women With Breast Cancer Using a Structured Online Writing Exercise: Results From the My Changed Body Randomized Controlled Trial.
    J Clin Oncol. 2018 Apr 24:JCO2017763318. doi: 10.1200/JCO.2017.76.3318.
    >> Share

  219. HAMOOD R, Hamood H, Merhasin I, Keinan-Boker L, et al
    Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study.
    J Clin Oncol. 2018 Apr 24:JCO2017763524. doi: 10.1200/JCO.2017.76.3524.
    >> Share

  220. DEGNIM AC, Winham SJ, Frank RD, Pankratz VS, et al
    Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia.
    J Clin Oncol. 2018 Apr 20:JCO2017759480. doi: 10.1200/JCO.2017.75.9480.
    >> Share

  221. DOWSETT M, Sestak I, Regan MM, Dodson A, et al
    Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
    J Clin Oncol. 2018 Apr 20:JCO2017764258. doi: 10.1200/JCO.2017.76.4258.
    >> Share

  222. WHEELER SB, Spencer JC, Pinheiro LC, Carey LA, et al
    Financial Impact of Breast Cancer in Black Versus White Women.
    J Clin Oncol. 2018 Apr 18:JCO2017776310. doi: 10.1200/JCO.2017.77.6310.
    >> Share

  223. KORNBLUM N, Zhao F, Manola J, Klein P, et al
    Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of
    J Clin Oncol. 2018 Apr 17:JCO2017769331. doi: 10.1200/JCO.2017.76.9331.
    >> Share

  224. WANG SY, Dang W, Richman I, Mougalian SS, et al
    Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
    J Clin Oncol. 2018 Apr 16:JCO2017765941. doi: 10.1200/JCO.2017.76.5941.
    >> Share

  225. REINER AS, Sisti J, John EM, Lynch CF, et al
    Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
    J Clin Oncol. 2018 Apr 5:JCO2017773424. doi: 10.1200/JCO.2017.77.3424.
    >> Share

    March 2018
  226. HERSHMAN DL, Till C, Shen S, Wright JD, et al
    Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials.
    J Clin Oncol. 2018 Mar 27:JCO2017774414. doi: 10.1200/JCO.2017.77.4414.
    >> Share

  227. MASSARWEH SA, Sledge GW, Miller DP, McCullough D, et al
    Molecular Characterization and Mortality From Breast Cancer in Men.
    J Clin Oncol. 2018 Mar 27:JCO2017768861. doi: 10.1200/JCO.2017.76.8861.
    >> Share

  228. JAGSI R, Griffith KA, Bellon JR, Woodward WA, et al
    Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.
    J Clin Oncol. 2018 Mar 20:JCO2017772665. doi: 10.1200/JCO.2017.77.2665.
    >> Share

  229. UNTCH M, von Minckwitz G, Gerber B, Schem C, et al
    Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
    J Clin Oncol. 2018 Mar 15:JCO2017759175. doi: 10.1200/JCO.2017.75.9175.
    >> Share

  230. KATZ SJ, Ward KC, Hamilton AS, Mcleod MC, et al
    Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer.
    J Clin Oncol. 2018 Mar 12:JCO2017762369. doi: 10.1200/JCO.2017.76.2369.
    >> Share

  231. WEDAM SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, et al
    US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.
    J Clin Oncol. 2018 Mar 9:JCO2017746917. doi: 10.1200/JCO.2017.74.6917.
    >> Share

    February 2018
  232. WHARAM JF, Zhang F, Lu CY, Wagner AK, et al
    Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment.
    J Clin Oncol. 2018 Feb 28:JCO2017752501. doi: 10.1200/JCO.2017.75.2501.
    >> Share

  233. ZARDAVAS D, Te Marvelde L, Milne RL, Fumagalli D, et al
    Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
    J Clin Oncol. 2018 Feb 22:JCO2017748301. doi: 10.1200/JCO.2017.74.8301.
    >> Share

  234. WAPNIR IL, Price KN, Anderson SJ, Robidoux A, et al
    Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.
    J Clin Oncol. 2018 Feb 14:JCO2017765719. doi: 10.1200/JCO.2017.76.5719.
    >> Share

  235. KENNEDY L, Bhatta S, Hechmati G, Buchanan J, et al
    Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases.
    J Clin Oncol. 2018 Feb 1:JCO2017770115. doi: 10.1200/JCO.2017.77.0115.
    >> Share

    January 2018
  236. NEUMAN HB, Schumacher JR, Francescatti AB, Adesoye T, et al
    Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01).
    J Clin Oncol. 2018 Jan 31:JCO2017755389. doi: 10.1200/JCO.2017.75.5389.
    >> Share

  237. PIVOT X, Bondarenko I, Nowecki Z, Dvorkin M, et al
    Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive E
    J Clin Oncol. 2018 Jan 26:JCO2017740126. doi: 10.1200/JCO.2017.74.0126.
    >> Share

  238. TRAINA TA, Miller K, Yardley DA, Eakle J, et al
    Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
    J Clin Oncol. 2018 Jan 26:JCO2016713495. doi: 10.1200/JCO.2016.71.3495.
    >> Share

  239. LAENKHOLM AV, Jensen MB, Eriksen JO, Rasmussen BB, et al
    PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.
    J Clin Oncol. 2018 Jan 25:JCO2017746586. doi: 10.1200/JCO.2017.74.6586.
    >> Share

  240. HAWLEY ST, Li Y, An LC, Resnicow K, et al
    Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial.
    J Clin Oncol. 2018 Jan 24:JCO2017748442. doi: 10.1200/JCO.2017.74.8442.
    >> Share

  241. DIELI-CONWRIGHT CM, Courneya KS, Demark-Wahnefried W, Sami N, et al
    Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2018 Jan 22:JCO2017757526. doi: 10.1200/JCO.2017.75.7526.
    >> Share

  242. HOLOWATYJ AN, Cote ML, Ruterbusch JJ, Ghanem K, et al
    Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
    J Clin Oncol. 2018 Jan 17:JCO2017745448. doi: 10.1200/JCO.2017.74.5448.
    >> Share

  243. ZIVANOVIC BUJAK A, Dawson SJ
    Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer.
    J Clin Oncol. 2018 Jan 3:JCO2017765461. doi: 10.1200/JCO.2017.76.5461.
    >> Share

  244. STOVER DG, Parsons HA, Ha G, Freeman SS, et al
    Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.
    J Clin Oncol. 2018 Jan 3:JCO2017760033. doi: 10.1200/JCO.2017.76.0033.
    >> Share

    December 2017
  245. BUTOW PN, Turner J, Gilchrist J, Sharpe L, et al
    Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence.
    J Clin Oncol. 2017;35:4066-4077.
    >> Share

  246. JOHNSTON SRD, Hegg R, Im SA, Park IH, et al
    Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Br
    J Clin Oncol. 2017 Dec 15:JCO2017747824. doi: 10.1200/JCO.2017.74.7824.
    >> Share

  247. BLUM JL, Robert N, Andersen J, Favret A, et al
    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer.
    J Clin Oncol. 2017 Dec 11:JCO2017753756. doi: 10.1200/JCO.2017.75.3756.
    >> Share

    November 2017
  248. HENRY NL, Unger JM, Schott AF, Fehrenbacher L, et al
    Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.
    J Clin Oncol. 2017 Nov 14:JCO2017746651. doi: 10.1200/JCO.2017.74.6651.
    >> Share

  249. HWONG AR, Mangurian C
    Improving Breast Cancer Screening and Care for Women With Severe Mental Illness.
    J Clin Oncol. 2017 Nov 2:JCO2017760462. doi: 10.1200/JCO.2017.76.0462.
    >> Share

    October 2017
  250. GANZ PA, Romond EH, Cecchini RS, Rastogi P, et al
    Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Pacl
    J Clin Oncol. 2017 Oct 26:JCO2017741165. doi: 10.1200/JCO.2017.74.1165.
    >> Share

  251. JEMAL A, Robbins AS, Lin CC, Flanders WD, et al
    Factors That Contributed to Black-White Disparities in Survival Among Nonelderly Women With Breast Cancer Between 2004 and 2013.
    J Clin Oncol. 2017 Oct 16:JCO2017737932. doi: 10.1200/JCO.2017.73.7932.
    >> Share

  252. VAN POZNAK C, Somerfield MR, Barlow WE, Biermann JS, et al
    Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
    J Clin Oncol. 2017 Oct 16:JCO2017754614. doi: 10.1200/JCO.2017.75.4614.
    >> Share

  253. SHAPIRO CL, Moriarty JP, Dusetzina S, Himelstein AL, et al
    Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
    J Clin Oncol. 2017 Oct 12:JCO2017737437. doi: 10.1200/JCO.2017.73.7437.
    >> Share

  254. ASDOURIAN MS, Swaroop MN, Sayegh HE, Brunelle CL, et al
    Association Between Precautionary Behaviors and Breast Cancer-Related Lymphedema in Patients Undergoing Bilateral Surgery.
    J Clin Oncol. 2017 Oct 4:JCO2017737494. doi: 10.1200/JCO.2017.73.7494.
    >> Share

  255. GOETZ MP, Toi M, Campone M, Sohn J, et al
    MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
    J Clin Oncol. 2017 Oct 2:JCO2017756155. doi: 10.1200/JCO.2017.75.6155.
    >> Share

    September 2017
  256. WU JW, Azoulay L, Majdan A, Boivin JF, et al
    Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
    J Clin Oncol. 2017 Sep 27:JCO2017734491. doi: 10.1200/JCO.2017.73.4491.
    >> Share

  257. IGLAY K, Santorelli ML, Hirshfield KM, Williams JM, et al
    Impact of Preexisting Mental Illness on All-Cause and Breast Cancer-Specific Mortality in Elderly Patients With Breast Cancer.
    J Clin Oncol. 2017 Sep 21:JCO2017734947. doi: 10.1200/JCO.2017.73.4947.
    >> Share

    February 2017
  258. LYMAN GH, Somerfield MR, Bosserman LD, Perkins CL, et al
    Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    J Clin Oncol. 2017;35:561-564.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016